Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05014815 · ClinicalTrials.gov registry record · Phase 2
Ociperlimab With Tislelizumab and Chemotherapy in Participants With Untreated Metastatic Non-Small Cell Lung Cancer
A Phase 2 study, sponsored by BeiGene.
- Completed
- Registry status
- Phase 2
- Development phase
- 272
- Enrollment target
NCT05014815: Completed Phase 2 study, sponsored by BeiGene.
NCT05014815 is a Phase 2 study that has completed, run by BeiGene. The registered enrollment target is 272 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (105% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05014815, a Phase 2 study, has completed, sponsored by BeiGene.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 272 participants
- Enrollment target
Study Summary
This study aimed to evaluate the safety and effectiveness of ociperlimab combined with tislelizumab and chemotherapy, compared to tislelizumab and chemotherapy alone, in participants with non-small cell lung cancer (NSCLC) that was locally advanced, could not be removed by surgery, or had spread to other parts of the body.
Primary Outcome
PFS was defined as the time from randomization to the first objectively documented disease progression as assessed by the investigator per Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST v1.1) or death from any cause, whichever occurred first. Median PFS was estimated using the Kaplan-Meier method.
Interventions
- DRUG Carboplatin
- DRUG Tislelizumab
- DRUG Paclitaxel
- DRUG Nab paclitaxel
- DRUG Ociperlimab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 272 participants |
| Start Date | 2021-11-16 |
| Est. Completion | 2024-09-04 |
| Phase | Phase 2 |
What the finished NCT05014815 record still lists
NCT05014815 is an interventional study that assigns participants to a tested intervention. The registered 272 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (105% higher).
The record links to 0 conditions, and to 5 interventions - of which Carboplatin is the first listed.
NCT05014815 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05014815 about?
NCT05014815 is a clinical study titled "Ociperlimab With Tislelizumab and Chemotherapy in Participants With Untreated Metastatic Non-Small Cell Lung Cancer". This study aimed to evaluate the safety and effectiveness of ociperlimab combined with tislelizumab and chemotherapy, compared to tislelizumab and chemotherapy alone, in participants with non-small cell lung cancer (NSCLC) that was locally advanced, could not be removed by surgery, or had spread to ...
What is the current status of trial NCT05014815?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 272 participants. The study started on 2021-11-16. Estimated completion is 2024-09-04.
What interventions are being tested in trial NCT05014815?
The interventions under investigation include: Carboplatin (DRUG), Tislelizumab (DRUG), Paclitaxel (DRUG), Nab paclitaxel (DRUG), Ociperlimab (DRUG).
Who is sponsoring clinical trial NCT05014815?
This trial is sponsored by BeiGene, which has 65 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05014815's enrollment target sits among peer trials
272 204th of 2000 higher than 1,796 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02468024 · 272 participants · Phase 3
JoLT-Ca Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) for Lung Cancer
- NCT05519449 · 272 participants · Phase 1
Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
- NCT06035939 · 272 participants · NA
SMYLS Multi-site Trial
- NCT06083051 · 272 participants · NA
Differences in Postoperative Symptoms With Four Ureteral Stents
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI